4.7 Article

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 73, Issue 10, Pages 1819-1825

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2013-203425

Keywords

-

Categories

Funding

  1. Arthritis Research UK [18475] Funding Source: Medline
  2. Versus Arthritis [18475] Funding Source: Medline
  3. National Institute for Health Research [NF-SI-0508-10299] Funding Source: researchfish
  4. Versus Arthritis
  5. Cancer Research UK [18475] Funding Source: researchfish

Ask authors/readers for more resources

Objective To study the relationship of spinal inflammation and fatty degeneration (FD) as detected by MRI and new bone formation seen on conventional radiographs (CRs) in ankylosing spondylitis (AS). Methods CRs at baseline, 2 years and 5 years and spinal MRIs at baseline and 2 years of 73 AS patients treated with infliximab in European AS Infliximab Cohort were available. Relative risks (RR) were calculated with a general linear model after adjustment for within-patient variation. Results In a total of 1466 vertebral edges (VEs) without baseline syndesmophytes, 61 syndesmophytes developed at 5 years, the majority of which (57.4%) had no corresponding detectable MRI lesions at baseline. VEs with both inflammation and FD at baseline had the highest risk (RR 3.3, p=0.009) for syndesmophyte formation at 5 years, followed by VEs that developed new FD or did not resolve FD at 2 years (RR=2.3, p=0.034), while inflammation at baseline with no FD at 2 years had the lowest risk for syndesmophyte formation at 5 years (RR=0.8). Of the VEs with inflammation at baseline, >70% resolved completely, 28.8% turned into FD after 2 years, but only 1 syndesmophyte developed within 5 years. Conclusions Parallel occurrence of inflammation and FD at baseline and development of FD without prior inflammation after 2 years were significantly associated with syndesmophyte formation after 5 years of antitumour necrosis factor (TNF) therapy. However, the sequence 'inflammation-FD-new bone formation' was rarely observed, an argument against the TNF-brake hypothesis. Whether an early suppression of inflammation leads to a decrease of the risk for new bone formation remains to be demonstrated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial

T. Rusman, M. A. C. van der Weijden, M. T. Nurmohamed, C. J. van Denderen, R. B. M. Landewe, P. M. Bet, C. M. A. van der Bijl, C. J. Van der Laken, I. E. van der Horst-Bruinsma

Summary: The study found that 16 weeks of etanercept treatment did not have an impact on disease activity, the chance of biological treatment, or radiographic progression in patients with suspected non-radiographic axial spondyloarthritis.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Instrument selection for the ASAS core outcome set for axial spondyloarthritis

Victoria Navarro-Compan, Anne Boel, Annelies Boonen, Philip J. Mease, Maxime Dougados, Uta Kiltz, Robert B. M. Landewe, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M. Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, Desiree van der Heijde

Summary: This study aims to define the instruments for the Assessment of SpondyloArthritis international Society-Outcomes Measures in Rheumatology core domain set for axial spondyloarthritis (axSpA). The study selected core outcome instruments through a systematic literature review and assessment of the instruments' psychometric properties. Additionally, the study endorsed additional instruments to enhance the evaluation of axSpA trials.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro

Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.

RHEUMATOLOGY (2023)

Article Rheumatology

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022

Kevin L. Winthrop, John D. Isaacs, Philip J. Mease, Dimitrios T. Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R. Lories, Daniel Aletaha, Iain B. McInnes, Tom W. J. Huizinga, Reinhard E. Voll, Ellen M. Gravallese, Ferry C. Breedveld, Josef S. Smolen

Summary: This article summarizes the unmet clinical and scientific needs in the field of rheumatology. It highlights the importance of clinical trial design innovation and the need to better understand the natural history of rheumatic diseases. The article also identifies the specific unmet needs in different rheumatological disease-specific groups and emphasizes the importance of developing therapies and therapeutic strategies for treatment-refractory disease.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu

Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Controversies in rheumatology: telemedicine-friend or foe?

Christian Dejaco, Robert B. M. Landewe

Summary: Telemedicine is increasingly used in rheumatology for triage, disease activity monitoring, and patient education. While it offers convenience, there are risks of losing essential information and challenges in building trusting relationships. It is important to complement telemedicine with traditional face-to-face visits for more efficient healthcare.

RHEUMATOLOGY (2023)

Article Rheumatology

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020

Katinka Albrecht, Anja Strangfeld, Ursula Marschall, Johanna Callhoff

Summary: This study investigates the prevalence, incidence, and medication of interstitial lung disease (ILD) among individuals with rheumatoid arthritis (RA) in Germany. It finds that RA-ILD is rare and mainly affects elderly individuals. Although there is no trend in incidence, treatment strategies have expanded, and specialist care is necessary to provide disease-specific therapies.

RMD OPEN (2023)

Article Rheumatology

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex

Katinka Albrecht, Anne Constanze Regierer, Anja Strangfeld, Ursula Marschall, Johanna Callhoff

Summary: This study examined the use of multiple medications in patients with psoriatic arthritis (PsA) and found that the frequency of medication use was significantly higher compared to the control group, particularly for musculoskeletal, immunomodulatory, cardiovascular, alimentary tract/metabolic, and nervous system drugs. Polypharmacy was common in PsA and increased with age and comorbidity, affecting both men and women equally.

RMD OPEN (2023)

Article Rheumatology

Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years

Caroline Ensslin, Raphael Micheroli, Seraphina Kissling, Andrea Gotschi, Kristina Burki, Rene Bram, Manouk de Hooge, Xenofon Baraliakos, Michael J. Nissen, Burkhard Moller, Pascale Exer, Michael Andor, Oliver Distler, Almut Scherer, Adrian Ciurea

Summary: This study investigated sex differences in spinal radiographic progression in axial spondyloarthritis. The results showed that spinal radiographic progression was more severe in men compared to women, with three times higher odds of progression in male patients, and this difference was mediated in part through an increase in baseline radiographic damage.

RMD OPEN (2023)

Article Rheumatology

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial

Rosalinde Stal, Sofia Ramiro, Desiree van der Heijde, Floris A. van Gaalen, Xenofon Baraliakos, Pedro M. Machado, Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert Landewe, Alexandre Sepriano

Summary: In patients with radiographic axial spondyloarthritis, vertebral corner inflammation can lead to the development of syndesmophytes, but only a small portion of this effect is explained by vertebral corner fat deposition.

RMD OPEN (2023)

Correction Rheumatology

Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target (kead155, 2023)

Janne W. Bolt, Caroline J. Aalbers, Laura Walet, Leonieke J. J. van Mens, Christiaan van Denderen, Irene van der Horst-Bruinsma, Lisa G. M. van Baarsen, Robert Landewe, Marleen G. H. van de Sande

RHEUMATOLOGY (2023)

No Data Available